scholarly journals New emerging therapies in the management of chronic lymphocytic leukemia

2016 ◽  
Vol 12 (5) ◽  
pp. 3051-3054 ◽  
Author(s):  
Xiao-Lin Li ◽  
Ci-Xian Zhang
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Emerging Therapies

Chronic Lymphocytic Leukemia: New Concepts and Emerging Therapies

2009 ◽  
Vol 10 (1-2) ◽  
pp. 16-32 ◽  
Author(s):  
Tahamtan Ahmadi ◽  
Tapan Maniar ◽  
Stephen Schuster ◽  
Edward Stadtmauer
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
New Concepts ◽  
Emerging Therapies

Emerging therapies for refractory chronic lymphocytic leukemia

2014 ◽  
Vol 56 (2) ◽  
pp. 285-292 ◽  
Author(s):  
Nadine Kutsch ◽  
Michael Hallek ◽  
Barbara Eichhorst
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Emerging Therapies

scholarly journals Current and future treatment strategies in chronic lymphocytic leukemia

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Krish Patel ◽  
John M. Pagel
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Unmet Need ◽  
Treatment Strategies ◽  
Progression Free Survival ◽  
Lymphocytic Leukemia ◽  
Free Survival ◽  
Emerging Therapies ◽  
B Cell Leukemia ◽  
Anti Cd20 ◽  
Insight Into

AbstractTreatment decisions for patients with chronic lymphocytic leukemia (CLL) are dependent on symptoms and classification into high-, medium-, or low-risk categories. The prognosis for CLL hinges, in part, on the presence or absence of less-favorable genetic aberrations, including del(17p), del(11q), TP53 dysfunction, and IGHV mutations, as these markers are associated with worse treatment response. Promising results from multiple clinical trials show emerging therapies targeting Burton tyrosine kinase, B-cell leukemia/lymphoma 2, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta result in better outcomes and prolonged progression-free survival for patients both with and without certain high-risk aberrations. Favorable outcomes using these novel oral targeted therapies, either alone or in combination with other treatments such as anti-CD20 antibodies, has led to their use almost entirely supplanting chemoimmunotherapy in the treatment of CLL. In this narrative review, we summarize the current clinical evidence for the use of targeted mono- and combination therapies for CLL, discuss new and next-generation treatment approaches currently in development, and provide insight into areas of unmet need for the treatment of patients with CLL.

Sign in / Sign up

Export Citation Format

Share Document